男性不妊症(Male Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)

【英語タイトル】Male Infertility - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6187IDB)・商品コード:GMDHC6187IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月30日
・ページ数:46
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における男性不妊症(Male Infertility)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・男性不妊症(Male Infertility)の概要
・男性不妊症(Male Infertility)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・男性不妊症(Male Infertility)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・男性不妊症(Male Infertility)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・男性不妊症(Male Infertility)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Male Infertility – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Male Infertility – Pipeline Review, H1 2015’, provides an overview of the Male Infertility’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Infertility and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Male Infertility
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Male Infertility and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Male Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Male Infertility pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Male Infertility
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Male Infertility pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Male Infertility Overview 7
Therapeutics Development 8
Pipeline Products for Male Infertility – Overview 8
Pipeline Products for Male Infertility – Comparative Analysis 9
Male Infertility – Therapeutics under Development by Companies 10
Male Infertility – Therapeutics under Investigation by Universities/Institutes 11
Male Infertility – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Male Infertility – Products under Development by Companies 14
Male Infertility – Products under Investigation by Universities/Institutes 15
Male Infertility – Companies Involved in Therapeutics Development 16
AlphaMab Co., Ltd 16
Pantarhei Bioscience BV 17
PharmaEssentia Corporation 18
PlasmaTech Biopharmaceuticals, Inc. 19
Zydus Cadila Healthcare Limited 20
Male Infertility – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
(oxytocin + estrogen) – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Biosimilar 4 for Acute Myocardial Infarction and Infertility – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Biosimilar 5 for Infertility – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Biosimilar 6 for Infertility – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Biosimilar 7 for Infertility and Oncology – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LM-001 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
LM-002 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MCS-5 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Oral Fertility Drugs – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PEG-FSH – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Agonize FSHR for Infertility – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecules for Male Infertility – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Stem Cell Therapy for Male Infertility – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Male Infertility – Recent Pipeline Updates 43
Male Infertility – Dormant Projects 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

[List of Tables]
Number of Products under Development for Male Infertility, H1 2015 8
Number of Products under Development for Male Infertility - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Male Infertility - Pipeline by AlphaMab Co., Ltd, H1 2015 16
Male Infertility - Pipeline by Pantarhei Bioscience BV, H1 2015 17
Male Infertility - Pipeline by PharmaEssentia Corporation, H1 2015 18
Male Infertility - Pipeline by PlasmaTech Biopharmaceuticals, Inc., H1 2015 19
Male Infertility - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 20
Assessment by Monotherapy Products, H1 2015 21
Assessment by Combination Products, H1 2015 22
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 29
Male Infertility Therapeutics - Recent Pipeline Updates, H1 2015 43
Male Infertility - Dormant Projects, H1 2015 44

[List of Figures]
Number of Products under Development for Male Infertility, H1 2015 8
Number of Products under Development for Male Infertility - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 21
Number of Products by Top 10 Targets, H1 2015 23
Number of Products by Stage and Top 10 Targets, H1 2015 24
Number of Products by Top 10 Mechanism of Actions, H1 2015 25
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
Number of Products by Top 10 Molecule Types, H1 2015 28
Number of Products by Stage and Top 10 Molecule Types, H1 2015 29

【掲載企業】

AlphaMab Co., Ltd
Pantarhei Bioscience BV
PharmaEssentia Corporation
PlasmaTech Biopharmaceuticals, Inc.
Zydus Cadila Healthcare Limited

★調査レポート[男性不妊症(Male Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6187IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[男性不妊症(Male Infertility):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆